Intravenous @entity2643 in the treatment of various XXXX following cardiac operations.

@entity1 @entity1671 @entity2643 @entity1165 @entity390 @entity713 @entity1283 @entity551 @entity2224 @entity1540 @entity943
In a group of 95 @entity1 having cardiac operations with extracorporeal circulation, intravenous (IV) @entity2643 , administered in doses of 2.5 to 5 mg/kg, was used in the treatment of various perioperative @entity943 . Conversion to sinus rhythm was achieved in 55 (61%) of 90 @entity1 with @entity943 , the other @entity1 showing a satisfactory slowing of their heart rate. Total suppression and control was obtained in 18 @entity1 with persistent @entity1540 associated with various @entity943 . @entity2643 was administered in five @entity1 with life-threatening @entity943 resistant to other antiarrhythmic agents: Suppression was obtained in one of two @entity1 with recurrent @entity1165 and control was achieved in three @entity1 with repetitive @entity1165 and @entity2224 , allowing the effective use of intra-aortic balloon counterpulsation (IABP) needed for hemodynamic support. Seven @entity1 experienced minor side effects such as @entity390 or @entity1671 . No complete @entity713 was noted. Significant @entity551 occurred at the end of the IV injection in 17 (18%) @entity1 . In all but five @entity1 , hypotenion was transient, without clinical complications. In the five others, adrenergic drugs in four cases and IABP in one case were necessary. Those five @entity1 had marked @entity1283 with poor myocardial contractility. IV bolus injection of @entity2643 seems prohibited in such @entity1 ; constant infusion would be preferable.
